Key result
SOX2OT knockdown reduced myocardial injury and collagen deposition in heart failure mice by inhibiting the TGF-β1/Smad3 pathway, identifying a novel SOX2OT/Smad3 positive feedback loop.
Why the study?
LncRNA SOX2OT is associated with myocardial fibrosis in heart failure, but its specific role remained to be investigated.
Does SOX2OT knockdown reduce myocardial fibrosis in isoprenaline-induced heart failure models?
Does SOX2OT knockdown reduce myocardial fibrosis in isoprenaline-induced heart failure models?
SOX2OT promotes myocardial fibrosis in heart failure via a positive feedback loop with Smad3, suggesting it as a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
SOX2OT inhibition may limit fibrosis in experimental HF; leaves open clinical translation of this Smad3 loop.
Long noncoding RNA SOX2OT is associated with myocardial fibrosis (MF) in heart failure (HF). This article aims to investigate the role of SOX2OT in MF. We constructed HF mouse models by subcutaneous injection of isoprenaline (ISO). Cardiac fibroblasts (CFs) were treated with ISO to induce MF.Hematoxylin-eosin, Masson, and Sirius-red staining were used to identify myocardial injury and collagen deposition in heart tissues. The relationship among SOX2OT, miR-138-5p, TGF-β1, and Smad3 were evaluated by chromatin immunoprecipitation and luciferase reporter assay. The gene and protein expression were verified by quantitative real-time PCR and western blot. We found that SOX2OT was up-regulated in HF mice and ISO-induced CFs. SOX2OT knockdown reduced myocardial injury and collagen deposition in HF mice. The expression of collagen I, α-SMA, TGF-β1, and p-Smad3 were inhibited by SOX2OT down-regulation in HF mice and ISO-induced CFs. Furthermore, TGF-β1 was a target gene of miR-138-5p and indirectly regulated by SOX2OT. SOX2OT promoted MF in HF by activating TGF-β1/Smad3, and then Smad3 interacted with the SOX2OT promoter and formed a positive feedback loop. In conclusion, our work verifies that SOX2OT/Smad3 feedback loop promotes MF in HF. Thus, SOX2OT is potentially a novel therapeutic target for MF in HF.
No takes yet. Share an insight, caveat, or question.
Ou et al. (2020) studied Heart failure and myocardial fibrosis. SOX2OT knockdown vs. Control (HF mice without knockdown) was evaluated on Myocardial injury and collagen deposition. SOX2OT knockdown reduced myocardial injury and collagen deposition in heart failure mice by inhibiting the TGF-β1/Smad3 pathway, identifying a novel SOX2OT/Smad3 positive feedback loop.
Synapse has enriched 10 related papers. Consider them for comparative context: